Loss of CDKN2A promoter methylation coincides with the epigenetic transdifferentiation of uterine myosarcomatous cells

International Journal of Gynecological Pathology

Volumn 35, Issue 4, 2016, Pages 309-315

  Roncati, Luca ^a   Barbolini, Giuseppe ^a   Sartori, Giuliana ^a   Siopis, Elena ^b   Pusiol, Teresa ^c   Maiorana, Antonio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Local Health Authority   (Italy)

^c Santa Maria Del Carmine Hospital   (Italy)

Author keywords

CDKN2A promoter; Leiomyosarcoma; Loss of heterozygosity (LOH); Rhabdomyosarcoma; Uterus

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CONTRAST MEDIUM; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DESMIN; EOSIN; EPIRUBICIN; HEMATOXYLIN; IFOSFAMIDE; PHOSPHOTUNGSTIC ACID; CDK2AP2 PROTEIN, HUMAN; CDKN2A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; ONCOPROTEIN; P16 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL TRANSDIFFERENTIATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; METHYLATION; MITOSIS INDEX; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; STRIATED MUSCLE; UTERUS SARCOMA; DNA METHYLATION; GENETICS; LEIOMYOSARCOMA; METABOLISM; PATHOLOGY; RHABDOMYOSARCOMA; SARCOMA; TUMOR SUPPRESSOR GENE; UTERINE NEOPLASMS;

CELL TRANSDIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LOSS OF HETEROZYGOSITY; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; RHABDOMYOSARCOMA; SARCOMA; UTERINE NEOPLASMS;

EID: 84975166680     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000181     Document Type: Article

References (32)

1. D'Angelo E, Bradley J, Quade BJ, et al. Uterine smooth muscle tumors. In: Mutter GL, Prat J, eds. Pathology of the Female Reproductive Tract. 3rd ed. Philadelphia: Churchill Livingston Elsevier; 2014:19.
2. Bapat K, Brustein S. Uterine sarcoma with liposarcomatous differentiation. Report of a case and review of the literature. Int J Gynecol Obstet 1989;28:71-5.
3. Vakiani M, Mawad J, Talerman A. Heterologus sarcomas of the uterus. Int J Gynecol Pathol 1982;1:211-9.
4. Stout AP. Mesenchymoma, the mixed tumor of mesenchymal derivatives. Ann Surg 1948;127:278-90.
5. Shintaku M, Sekiyama K. Leiomyosarcoma of the uterus with focal rhabdomyosarcomatous differentiation. Int J Gynecol Pathol 2004;23:188-92.
6. Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol 2011;12:79-89.
7. Igaki H, Sasaki H, Kishi T, et al. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 1994;203:1090-5.
8. Bartsch D, Shevlin DW, Tung WS, et al. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer 1995;14:189-95.
9. Liu L, Lassam NJ, Slingerland JM, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995;11:405-12.
10. Khor GH, Froemming GR, Zain RB, et al. DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. Int J Med Sci 2013;10:1727-39.
11. Demokan S, Chuang A, Suoǧlu Y, et al. Promoter methylation and loss of p16 (INK4a) gene expression in head and neck cancer. Head Neck 2012;34:1470-5.
12. Jabonowski Z, Reszka E, Gromadzińska J, et al. Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch Med Sci 2011;7:512-6.
13. Sharma G, Mirza S, Prasad CP, et al. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007;80:1873-81.
14. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:177-8.
15. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Prog Nat Sci 1996;93:9821-6.
16. Roncaroli F, Eusebi V. Rhabdomyoblastic differentiation in a leiomyosarcoma of the retroperitoneum. Hum Pathol 1996;27: 310-3.
17. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995;55:2988-94.
18. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012;130:1715-25.
19. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
20. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-206.
21. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999;18:5311-7.
22. Patapoutian A, Wold BJ, Wagner RA. Evidence for developmentally programmed transdifferentiation in mouse esophageal muscle. Science 1995;270:1818-21.
23. Kablar B, Tajbakhsh S, Rudnicki MA. Transdifferentiation of esophageal smooth to skeletal muscle is myogenic bHLH factor-dependent. Development 2000;127:1627-39.
24. Martin-Reay DG, Christ ML, LaPata RE. Uterine leiomyoma with skeletal muscle differentiation. Report of a case. Am J Clin Pathol 1991;96:344-7.
25. Fornelli A, Pasquinelli G, Eusebi V. Leiomyoma of the uterus showing skeletal muscle differentiation: a case report. Hum Pathol 1999;30:356-9.
26. Leung F, Terzibachian JJ, Aouar Z, et al. Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases. Gynecol Obstet Fertil 2008;36:628-35.
27. Oshiro Y, Shiratsuchi H, Oda Y. Rhabdoid features in leiomyosarcoma of soft tissue: with special reference to aggressive behaviour. Mod Pathol 2009;13:1211-8.
28. Kanthan R, Senger JL, Diudea D. Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins. World J Surg Oncol 2010; 8:60.
29. Buza N, Tavassoli FA. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. Int J Gynecol Pathol 2009;28:514-21.
30. Abeln EC, Smit VT, Wessels JW, et al. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours. J Pathol 1997;183:424-31.
31. Sajjad Y. Development of the genital ducts and external genitalia in the early human embryo. J Obstet Gynaecol Res 2010;36:929-37.
32. Robinson-Bennett B, Belch RZ, Han AC. Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus. Int J Gynecol Cancer 2006;16:1354-7.